From New Scientist.com:
NewScientist.com - NEWSFLASH
Deadly Asian bird flu is in Europe
The bird flu outbreak in turkeys in northwest Turkey was caused by
the same strain of H5N1 bird flu that was isolated in August 2005
from poultry in Siberia - meaning that the deadly strain has reached
Europe as feared.
It is the same virus as found in wild birds in Mongolia and Qinghai
Lake in China in spring 2004. Those in turn derived from the H5N1
that has spread across East Asia, so far killing at least 60 people.
It is thought to pose the greatest current risk of a human flu
pandemic.
Click on the link below for the full story on NewScientist.com/news:
http://www.newscientist.com/article.ns?id=dn8150
And:
Bird flu: kick-start vaccination or face the consequences
15 October 2005
From New Scientist Print Edition
Debora Mackenzie
Kristin Choo
SUDDENLY, the threat of avian flu is getting some serious attention in the US. Representatives of 80 countries met in Washington DC last week to discuss strategies to contain outbreaks of the virus.
Meanwhile Michael Leavitt, US Secretary of Health and Human Services, this week made his first official trip to Asia to encourage leaders in the region to do more to stop the virus spreading. And a decision by the US senate to earmark an extra $4 billion to protect the country against a flu pandemic is awaiting approval by the House of Representatives.
These moves are welcome, but do not go far enough, flu experts say. Substantial commercial, political and bureaucratic barriers remain that will stop us being able to vaccinate enough of the world's people to contain any pandemic. What is urgently required is a global plan to combat the threat.
“Because the virus is new to our immune systems, people will need two injections. That halves the number we can protect”The problem boils down to numbers. A hybrid vaccine virus has already been produced that could immunise people against the H5N1 bird flu virus. But manufacturers can't make enough of it. Production capacity will not significantly increase any time soon, beyond a few new plants already under construction in Europe, and with the equipment available they can make only a few kilograms of the viral protein that forms the basis of the vaccine. If each dose contains 15 micrograms (g) of viral protein, as in vaccines against ordinary flu, that's enough for no more than 900 million doses of vaccine over a normal six-month production cycle (New Scientist, 28 February 2004, p 36).
But that doesn't mean 900 million people can be protected. Because H5N1 is new to our immune system, people will need two vaccinations a few weeks apart. That halves the number who can be protected within six months to 450 million.
And even that is likely to be wildly optimistic. "This virus has done a number on us," says Robert Webster of St Jude Children's Research Hospital in Memphis, Tennessee. In August, human trials of the hybrid vaccine showed that each person would require two 90-g doses. That equates to enough vaccine worldwide for 75 million people, or around one quarter the US population.
The way round this, say vaccine experts, is to boost the power of the shots by combining them with a simple immunity-stimulating chemical called an adjuvant. Norbert Hehme at vaccine maker GlaxoSmithKline in Dresden, Germany, has made a vaccine that can induce full immunity against relatives of the H5 family of bird flu viruses with two doses of just 1.9 g each.
Given existing production capacity for H5N1, this would allow 3.5 billion people to be protected. That is as many as could practically be immunised, given other limitations, says David Fedson, founder of the vaccine industry's pandemic task force. But the US trials did not use adjuvant, despite warnings that without it only large doses would work (New Scientist, 26 March, p 10).
Trials of adjuvant with doses down to 7.5 g have begun in Australia and Hungary, and are planned in Canada, the US and Japan. But no one is looking at the smaller doses that would be needed to stretch the available vaccine as far as it needs to go.
"By not determining the lowest dose that is acceptably immunogenic, the vaccine companies have shown they do not understand the unforgiving arithmetic of pandemic vaccine supply," Fedson told New Scientist. "That means millions will not receive vaccine, and thousands will die. Economists call this an opportunity cost. I call it a tragedy."
Commercial considerations are also getting in the way. Companies have not yet worked out how to share patented techniques for making the vaccines, and are reluctant to start human trials on vaccines that have no guaranteed market. "If we have purchase guarantees from governments, that changes things," says Bram Palache of the Belgian-based vaccine maker Solvay. The US, UK and France, among others, have placed such orders in the past few months, which is why trials are now starting, But the constraints on vaccine production mean these orders may never be fulfilled.
There are political obstacles too. Nearly 70 per cent of the world's vaccine manufacturing capacity is in five countries in western Europe, and virus expert Albert Osterhaus of Erasmus University in Rotterdam, the Netherlands, predicts these countries will be reluctant to allow vaccine to be exported until their own populations are immunised.
Fedson, however, believes these barriers can be overcome. What is needed, he argues, is a well-funded international body along the lines of the Global Fund to Fight AIDS, Tuberculosis and Malaria, launched by the UN in 2002, which has spent $3 billion tackling these diseases. A similar body for pandemic flu, Fedson says, could coordinate vaccine development and fund the testing that will get us the low-dose, adjuvanted vaccine that may be needed to fight a global pandemic. "Wouldn't it be horrible if a pandemic comes and afterwards we discover we could have made far more vaccine?" he says. "We'll look like fools."
Such a body could also head off the political crisis that would ensue if vaccine-manufacturing countries decide to immunise their own people before allowing vaccine to be exported. "Can you imagine the conflict that would result if people in Bordeaux get vaccinated and people in Barcelona don't?" says Fedson. By paying into a global collaboration, he says, the "have-not" countries could ensure that they will get a share of vaccines made elsewhere..............
Full article here:
http://www.newscientist.com/channel/health/mg18825215.900